Phase
Condition
Bulimia
Anxiety Disorders
Hypochondriasis
Treatment
perceptual modulation
attentional modulation
naturalistic viewing
Clinical Study ID
Ages 18-40 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Body dysmorphic disorder: Inclusion:
males or females
ages 18-40
meet Diagnostic and Statistical Manual-5 (DSM-5) criteria for Body DysmorphicDisorder
have a Body Dysmorphic Disorder version of the Yale-Brown Obsessive-CompulsiveDisorder Scale (BDD-YBOCS) score of ≥20
primary appearance concerns of the face or head area
medication naïve or medication free for at least 8 weeks prior to enrollment
Inclusion Criteria:
Subclinical body dysmorphic disorder: Inclusion:
males or females
ages 18-40
have a score on the Dysmorphic Concern Questionnaire of ≥8 [1 standard deviation (STD) above population norms] - primary appearance concerns of the face or head area
medication naïve or medication free for at least 8 weeks prior to enrollment
Inclusion Criteria:
Healthy controls: Inclusion
Healthy males and females from any racial or ethnic background - ages 18-40
have a score on the Dysmorphic Concern Questionnaire of <8
Exclusion
Exclusion Criteria:
Body dysmorphic disorder: Exclusion
concurrent major Axis I disorders including substance use disorders, aside fromanxiety disorders or depressive disorders, as these comorbidities are very commonand the sample would otherwise be non-representative; however BDD must be theprimary diagnosis.
lifetime: bipolar disorder or psychotic disorder.
psychotropic medications, aside from a short half-life sedative/hypnotic forinsomnia, or a short half-life benzodiazepine as needed for anxiety but notexceeding a frequency of 3 doses in one week and not to be taken on the days of thetraining or MRI scan
current cognitive-behavioral therapy
Exclusion:
Subclinical body dysmorphic disorder: Exclusion
meet full DSM-5 criteria for Body Dysmorphic Disorder
current Axis I disorders including substance use disorders
lifetime: bipolar disorder or psychotic disorder
psychotropic medications, aside from a short half-life sedative/hypnotic forinsomnia, or a short half-life benzodiazepine as needed for anxiety but notexceeding a frequency of 3 doses in one week and not to be taken on the days of thetraining or MRI scan
current cognitive-behavioral therapy
Exclusion Criteria:
Healthy Controls: Exclusion
Any current Axis I disorder
lifetime: bipolar disorder or psychotic disorder
Psychiatric medication
Exclusion Criteria:
All participants: Exclusion
Neurological disorder
Pregnancy
Current major medical disorders that may affect cerebral metabolism such as diabetesor thyroid disorders - Current risk of suicide with a plan and intent
Ferromagnetic metal implantations or devices (electronic implants or devices,infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses,joints, rods or plates)
Visual acuity worse than 20/35 for each eye as determined by Snellen close visionacuity chart (vision will be tested with corrective lenses if participant usesthem).
Study Design
Study Description
Connect with a study center
Centre for Addiction and Mental Health
Toronto, Ontario M6J 1H3
CanadaActive - Recruiting
UCLA
Los Angeles, California 90095
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.